Please assess the completion status of the following clinical trial:

Trial Title: A Drug-drug Interaction Study Between GLPG1205 and a Cocktail of CYP450 Substrates in Healthy Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* healthy male, age 18-50 years~* BMI between 18-30 kg/m2~Exclusion Criteria:~* Poor or moderate metabolizer for CYP2C9 or CYP2C19 as determined by genotyping~* Having a contraindication as indicated in the respective Summary of Product Characteristics (or Package Leaflets) for warfarin, omeprazole or caffeine~* Intake of nutraceuticals within 3 weeks prior to dosing or within 6 times the elimination half life~* Intake of enzyme inducing or enzyme inhibiting drugs within 3 months prior to dosing~* Intake of vitamin K within 3 weeks prior to dosing~* Any condition that might interfere with the procedures or tests in this study~* Drug or alcohol abuse~* Smoking

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- GLPG1205 and single CYP450 substrate cocktail dose (Type: EXPERIMENTAL): Daily GLPG1205 administration from Day 1 to Day 12 Single GLPG1205 co-administration on Day 13 with CYP450 substrate cocktail
- Placebo and single CYP450 substrate cocktail dose (Type: PLACEBO_COMPARATOR): Daily Placebo administration from Day 1 to Day 12 Single Placebo co-administration on Day 13 with CYP450 substrate cocktail

Based on this trial design, predict the completion outcome and termination type (if applicable).